# Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation

> **NCT02149160** · PHASE2 · UNKNOWN · sponsor: **FORUM Pharmaceuticals Inc** · enrollment: 30 (estimated)

## Conditions studied

- Granulin Mutation

## Interventions

- **DRUG:** FRM-0334
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02149160
- **Lead sponsor:** FORUM Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-10
- **Primary completion:** 2016-08
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2016-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02149160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02149160, "Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02149160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*